TLOG has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TLOG has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
TetraLogic Pharmaceuticals's gross profit for the three months ended in Sep. 2016 was $0.00 Mil. TetraLogic Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Sep. 2016 was $0.00 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. TetraLogic Pharmaceuticals's gross profit for the three months ended in Sep. 2016 was $0.00 Mil. TetraLogic Pharmaceuticals's Revenue for the three months ended in Sep. 2016 was $0.00 Mil. Therefore, TetraLogic Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2016 was N/A%.
TetraLogic Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Sep. 2016 => No sustainable competitive advantage
The historical data trend for TetraLogic Pharmaceuticals's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TetraLogic Pharmaceuticals Annual Data | |||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | ||||||
Gross Profit | - | - | - | - | - |
TetraLogic Pharmaceuticals Quarterly Data | |||||||||||||||||||
Dec11 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | |
Gross Profit | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, TetraLogic Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's Gross Profit distribution charts can be found below:
* The bar in red indicates where TetraLogic Pharmaceuticals's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
TetraLogic Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2015 is calculated as
Gross Profit (A: Dec. 2015 ) | = | Revenue | - | Cost of Goods Sold |
= | 0 | - | 0 | |
= | 0.00 |
TetraLogic Pharmaceuticals's Gross Profit for the quarter that ended in Sep. 2016 is calculated as
Gross Profit (Q: Sep. 2016 ) | = | Revenue | - | Cost of Goods Sold |
= | 0 | - | 0 | |
= | 0.00 |
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
TetraLogic Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2016 is calculated as
Gross Margin % (Q: Sep. 2016 ) | = | Gross Profit (Q: Sep. 2016 ) | / | Revenue (Q: Sep. 2016 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 0.00 | / | 0 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
TetraLogic Pharmaceuticals (OTCPK:TLOG) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
TetraLogic Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Sep. 2016 => No sustainable competitive advantage
Thank you for viewing the detailed overview of TetraLogic Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Hudson Bay Capital Management Lp | other: See Remarks | 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Lazard Asset Management Llc | other: See Remarks | 30 ROCKEFELLER PLZ, 56TH FL., NEW YORK NY 10112 |
Nomura Holdings Inc | other: See Remarks | 1-13-1 NIHONBASHI, CHUO-KU, TOKYO M0 103-8645 |
Whitebox Multi-strategy Partners Lp | other: See Remarks | 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416 |
Pandora Select Partners, L.p. | other: See Remarks | 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416 |
Whitebox General Partner Llc | other: See Remarks | 3033 EXCELSIOR BLVD., SUITE 300, MINNEAPOLIS MN 55416 |
Highbridge Capital Management Llc | other: See Remarks | 277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172 |
Sander Gerber | other: See Remarks | C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Whitebox Concentrated Convertible Arbitrage Partners, L.p. | other: See Remarks | 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416 |
Whitebox Advisors Llc | other: See Remarks | 3033 EXCELSIOR BLVD., SUITE 500, MINNEAPOLIS MN 55416 |
Patrick Hutchison | officer: CFO & Treasurer | C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803 |
Clarus Ventures Ii, Llc | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Clarus Lifesciences Ii, L.p. | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Clarus Ventures Ii Gp, L.p. | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Nicholas Simon | 10 percent owner | 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.